Key result
Treatment with Alxn4100TPO improved 30-day survival and increased platelet counts in mice subjected to 9.5 Gy radiation and wound trauma, though it delayed wound healing.
Why the study?
Does Alxn4100TPO improve survival and mitigate hematopoietic radiation syndrome in mice subjected to radiation and wound trauma?
Does Alxn4100TPO improve survival and mitigate hematopoietic radiation syndrome in mice subjected to radiation and wound trauma?
Alxn4100TPO improves survival and mitigates hematopoietic radiation syndrome in a mouse model of combined radiation and wound trauma.
Answers are grounded in this paper and cite their sources.
Improves survival in a mouse radiation-wound model; leaves open translation to human countermeasures pending larger-species validation.
Ionizing radiation combined with trauma tissue injury (combined injury, CI) results in greater mortality and H-ARS than radiation alone (radiation injury, RI), which includes thrombocytopenia. The aim of this study was to determine whether increases in numbers of thrombocytes would improve survival and mitigate H-ARS after CI. We observed in mice that WBC and platelets remained very low in surviving RI animals that were given 9.5 Gy60Co-γ-photon radiation, whereas only lymphocytes and basophils remained low in surviving CI mice that were irradiated and then given skin wounds. Numbers of RBC and platelets, hemoglobin concentrations, and hematocrit values remained low in surviving RI and CI mice. CI induced 30-day mortality higher than RI. Radiation delayed wound healing by approximately 14 days. Treatment with a thrombopoietin receptor agonist, Alxn4100TPO, after CI improved survival, mitigated body-weight loss, and reduced water consumption. Though this therapy delayed wound-healing rate more than in vehicle groups, it greatly increased numbers of platelets in sham, wounded, RI, and CI mice; it significantly mitigated decreases in WBC, spleen weights, and splenocytes in CI mice and decreases in RBC, hemoglobin, hematocrit values, and splenocytes and splenomegaly in RI mice. The results suggest that Alxn4100TPO is effective in mitigating CI.
No takes yet. Share an insight, caveat, or question.
Kiang et al. (2017) studied Hematopoietic Radiation Syndrome and Combined Injury. Alxn4100TPO vs. vehicle was evaluated on 30-day mortality. Treatment with Alxn4100TPO improved 30-day survival and increased platelet counts in mice subjected to 9.5 Gy radiation and wound trauma, though it delayed wound healing.
Synapse has enriched 10 related papers. Consider them for comparative context: